Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-Resistant Pseudomonas aeruginosa in a Hollow Fibre Infection Model
Abstract
Aminoglycosides are commonly partnered with β-lactam antibiotics for empirical treatment of severe Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa. However, the optimal duration of aminoglycoside therapy when co-administered with β-lactam antibiotics remains poorly defined. This study compared the antibacterial efficacy of short (one-day, three-day) versus long course (seven-day) of tobramycin therapy, co-administered with piperacillin/tazobactam, against piperacillin/tazobactam-resistant clinical isolates of P. aeruginosa in a hollow fibre infection model (HFIM). A broth microdilution method was used to determine the minimum inhibitory concentration (MIC) of the antibiotics. The HFIM experiments were performed using two piperacillin/tazobactam-resistant clinical isolates, CTAP-32 and CTAP-72 (both with piperacillin/tazobactam MICs > 128 mg/L). The clinical dose of tobramycin (10 mg/kg/day IV) was simulated for one, three, and seven days, each in combination with piperacillin/tazobactam (4.5 g every six hours infused over 30 min). In the HFIM, the one-day, three-day, and seven-day courses of tobramycin administered with piperacillin/tazobactam resulted in comparable bacterial kill with ~3log10 CFU/mL bacterial density reduction within the first 8 h of treatment against the CTAP-32 bacterial isolate. Similarly, these three combination regimens resulted in equivalent bacterial killing effects against the CTAP-72 isolate with a ~5log10 CFU/mL bacterial reduction during the initial treatment period. However, despite this early decline, comparable bacterial regrowth was observed thereafter with the short versus the long course of tobramycin co-administered with piperacillin/tazobactam. In conclusion, short-course and long-course tobramycin therapy, when combined with piperacillin/tazobactam, achieved comparable antibacterial efficacy against P. aeruginosa isolates in the HFIM. However, these findings warrant further validation in clinical studies.
Related
- Severe Thrombocytopenia Induced by Re‐Exposure to Piperacillin/Tazobactam: A Case Report in Critically Ill Patient With COVID‐19
- Possible severe piperacillin-tazobactam–associated drug-induced liver injury after re-exposure: a case report
- Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters
- Prophylactic antibiotics for pancreaticoduodenectomy: study protocol for a multicenter randomized controlled trial comparing tazobactam/piperacillin versus ampicillin/sulbactam.
- Investigation of Carbapenemase Resistance Genes and Plasmid-Mediated Quinolone Resistance Genes in Ceftolozane/Tazobactam-Resistant Enterobacterales and Pseudomonas aeruginosa Isolates
BibTeX
@article{wale2026evaluation,
title = {{Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-Resistant Pseudomonas aeruginosa in a Hollow Fibre Infection Model}},
author = {Yalew Wale and Jason Roberts and Hayoung Won and Sheethal Reghu and Dusan Marjanovic and Getnet Assefa and Budi Permana and Brian Ford and Fekade Sime},
journal = {Antibiotics},
year = {2026},
month = jul,
doi = {10.3390/antibiotics15070685},
url = {https://hal.science/hal-05775198v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Evaluation of Short Versus Long Course of Tobramycin Combined with Piperacillin/Tazobactam Against Antibiotic-Resistant Pseudomonas aeruginosa in a Hollow Fibre Infection Model
AU - Yalew Wale
AU - Jason Roberts
AU - Hayoung Won
AU - Sheethal Reghu
AU - Dusan Marjanovic
AU - Getnet Assefa
AU - Budi Permana
AU - Brian Ford
AU - Fekade Sime
PY - 2026
DA - 2026/07/13
JO - Antibiotics
DO - 10.3390/antibiotics15070685
UR - https://hal.science/hal-05775198v1
AB - Aminoglycosides are commonly partnered with β-lactam antibiotics for empirical treatment of severe Gram-negative bacterial infections, including those caused by Pseudomonas aeruginosa. However, the optimal duration of aminoglycoside therapy when co-administered with β-lactam antibiotics remains poorly defined. This study compared the antibacterial efficacy of short (one-day, three-day) versus long course (seven-day) of tobramycin therapy, co-administered with piperacillin/tazobactam, against piperacillin/tazobactam-resistant clinical isolates of P. aeruginosa in a hollow fibre infection model (HFIM). A broth microdilution method was used to determine the minimum inhibitory concentration (MIC) of the antibiotics. The HFIM experiments were performed using two piperacillin/tazobactam-resistant clinical isolates, CTAP-32 and CTAP-72 (both with piperacillin/tazobactam MICs > 128 mg/L). The clinical dose of tobramycin (10 mg/kg/day IV) was simulated for one, three, and seven days, each in combination with piperacillin/tazobactam (4.5 g every six hours infused over 30 min). In the HFIM, the one-day, three-day, and seven-day courses of tobramycin administered with piperacillin/tazobactam resulted in comparable bacterial kill with ~3log10 CFU/mL bacterial density reduction within the first 8 h of treatment against the CTAP-32 bacterial isolate. Similarly, these three combination regimens resulted in equivalent bacterial killing effects against the CTAP-72 isolate with a ~5log10 CFU/mL bacterial reduction during the initial treatment period. However, despite this early decline, comparable bacterial regrowth was observed thereafter with the short versus the long course of tobramycin co-administered with piperacillin/tazobactam. In conclusion, short-course and long-course tobramycin therapy, when combined with piperacillin/tazobactam, achieved comparable antibacterial efficacy against P. aeruginosa isolates in the HFIM. However, these findings warrant further validation in clinical studies.
SN - 2079-6382
ER -